H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on MedinCell SA (MEDCL – Research Report) today and set a price target of €25.00.
Ram Selvaraju has given his Buy rating due to a combination of factors including the promising expansion opportunities for MedinCell’s UZEDY product. The FDA’s acceptance of the supplemental New Drug Application for UZEDY, aimed at treating bipolar disorder I, suggests a potential increase in the addressable market and revenue streams for MedinCell, as they stand to gain from royalties on net sales. The anticipated approval and launch of UZEDY for this new indication next year further supports the positive outlook.
Additionally, the progress of MedinCell’s TEV-44749, an olanzapine long-acting injectable, adds to the company’s growth potential. The successful completion of the pivotal Phase 3 trial and the achievement of primary endpoints in the SOLARIS study highlight the product’s efficacy and safety. With both UZEDY and TEV-44749 targeting widely-used atypical antipsychotic categories, MedinCell is well-positioned to benefit from robust market penetration and investor confidence, reinforcing the Buy rating.
In another report released on February 19, Kepler Capital also maintained a Buy rating on the stock with a €18.30 price target.